Seasonal Influenza vaccine

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

InfluenzaPneumococcal Vaccines

95 competitors in Influenza

#DrugCompanyPhaseTrials

1

Influenza Vaccine

Novartis

Phase 3

712

FLU Vaccine

GSK

Phase 3

83

Inactivated Influenza Vaccine

Sanofi

Phase 3

144

Lagevrio

Merck & Co.

Phase 2

25

Live Attenuated Zoster Vaccine

CChangchun BCHT Biotechnology Co.

Phase 3

126

Relenza

GGlaxo Dba Glaxosmithkline

Phase 3

57

Seasonal Influenza vaccine

Novartis

Phase 3

228

VAXIGRIP

GSK

Phase 3

89

Dexametasone

UUniversity of Malaya

Phase 3

110

GP681

JJiangxi Qingfeng Pharmaceutical Co. Ltd.

Phase 3

3Show 27 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Influenza22 trials

Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012

Completed·Novartis·Phase 2·NCT01344057·63 enrolled

Persistence of Immune Response After Vaccination With Influenza Vaccine

Completed·CCenters for Disease Control and Prevention, China·N/A·NCT01906190·207 enrolled

Improved Novel VaccIne CombinaTion InflUenza Study

Terminated·BBarinthus Biotherapeutics·Phase 2·NCT03300362·862 enrolled

Show 19 more trials

Effect of Tocilizumab to the Cellular Immune Response to Influenza Vaccine

Unknown status·TTel-Aviv Sourasky Medical Center·Phase 4·NCT01980836·40 enrolled

Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Children Aged 6 to 35 Month

Unknown status·CCenters for Disease Control and Prevention, China·Phase 3·NCT01040078·900 enrolled

Seasonal Influenza Vaccine Effectiveness Study in Kenya

Completed·GGideon Emukule··NCT01432340·10,000 enrolled

Comparison of Laser Assisted Epidermal to Intradermal Administration of Seasonal Influenza Vaccine

Completed·PPantec Biosolutions AG·Phase 1·NCT02988739·20 enrolled

Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults

Recruiting·UUniversity of Pennsylvania·Phase 4·NCT05108818·700 enrolled

Active Surveillance for Adverse Events Following Immunization With the Butantan Trivalent Influenza Vaccine (2018)

Completed·BButantan Institute··NCT03392207·403 enrolled

Study of Parenterally Administrated Adjuvanted Seasonal Influenza Vaccine in Healthy Elderly Volunteers

Unknown status·IIsconova AB·Phase 1·NCT01444482·110 enrolled

Adult Safety Study of 2009/2010 Seasonal Influenza Vaccine

Completed·AAlachua Government Services, Inc.·Phase 3·NCT01063088·211 enrolled

Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1, Seasonal Influenza Vaccine, Formulation 2009-2010

Completed·Novartis·Phase 2·NCT00956761·63 enrolled

Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2008/2009

Completed·Novartis·Phase 3·NCT00735410·134 enrolled

Two-site Intradermal Influenza Vaccination in Elderly

Completed·QQueen Saovabha Memorial Institute·N/A·NCT01202552·180 enrolled

Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response

Completed·EEmory University·Phase 4·NCT03701061·12 enrolled

Safety and Immunogenicity of Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009

Completed·Novartis·Phase 2·NCT00734734·64 enrolled

Active Surveillance for Adverse Events Following Immunization With the Influenza Vaccine Produced at Butantan Institute

Completed·BButantan Institute··NCT03057483·533 enrolled

Safety and Immunogenicity of One Dose of an Inactivated Trivalent Sub-unit Influenza Vaccine Administered to Non-elderly Adult and Elderly Subjects

Completed·Novartis·Phase 2·NCT01357265·125 enrolled

Heterologous Effect of Diptheria, Tetanus, Acellular Pertussis Vaccination on Influenza Challenge in the Elderly

Unknown status·CClifford Craig Medical Research Trust·N/A·NCT02765126·450 enrolled

Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) [Ph.Eur], Formulation 2009-2010, When Administered to Non-Elderly Adult and Elderly Subjects

Completed·Novartis·Phase 2·NCT00956449·126 enrolled

A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus

Completed·Inovio Pharmaceuticals·Phase 1·NCT01405885·116 enrolled

Safety and Immunogenicity of One Dose of a Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture Administered to Adult and Elderly Subjects

Completed·Novartis·Phase 3·NCT01422512·126 enrolled

Multiple Sclerosis2 trials

Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy

Completed·Bristol-Myers Squibb·Phase 3·NCT05028634·63 enrolled

Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)

Completed·Novartis·Phase 3·NCT01199861·138 enrolled

Immune Response1 trial

Effect of Drinking Fermented Milk on Immune Response

Completed·MMahidol University·N/A·NCT02909842·60 enrolled

Chronic Kidney Disease1 trial

The Effect and Safety of the Seasonal Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Not on Dialysis

Unknown status·NNational Cheng-Kung University Hospital·Phase 4·NCT02105519·200 enrolled

Vaccine Response1 trial

MTX Discontinuation and Vaccine Response

Completed·SSeoul National University Hospital·Phase 4·NCT02748785·277 enrolled

Details

Drug Info

Related News